Jeanne Gray - Relay Therapeutics Chief Officer
| RLAY Stock | USD 4.70 0.10 2.08% |
Executive
Jeanne Gray is Chief Officer of Relay Therapeutics
| Address | 399 Binney Street, Cambridge, MA, United States, 02139 |
| Phone | 617 370 8837 |
| Web | https://www.relaytx.com |
Relay Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2687) % which means that it has lost $0.2687 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4269) %, meaning that it created substantial loss on money invested by shareholders. Relay Therapeutics' management efficiency ratios could be used to measure how well Relay Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to drop to -0.48 in 2024. At this time, Relay Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 792.1 M in 2024, whereas Total Assets are likely to drop slightly above 838.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lisa Sinclair | Arvinas | N/A | |
| Christina MBA | Blueprint Medicines Corp | 48 | |
| Saurabh Sewak | Foghorn Therapeutics | N/A | |
| Adam Townsend | Apellis Pharmaceuticals | 47 | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Jared JD | Arvinas | 55 | |
| Edmund Dunn | Monte Rosa Therapeutics | 58 | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| Randy Teel | Arvinas | 44 | |
| Michael CPA | Blueprint Medicines Corp | 52 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Chad Cowan | Century Therapeutics | N/A | |
| JD Esq | Terns Pharmaceuticals | 55 | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
| Morgan Conn | Century Therapeutics | 55 | |
| Kristian MBA | Foghorn Therapeutics | 48 | |
| Nick MD | Century Therapeutics | N/A | |
| Cristiana Guiducci | Nurix Therapeutics | N/A | |
| Jolie JD | C4 Therapeutics | 47 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.27 |
Relay Therapeutics Leadership Team
Elected by the shareholders, the Relay Therapeutics' board of directors comprises two types of representatives: Relay Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Relay. The board's role is to monitor Relay Therapeutics' management team and ensure that shareholders' interests are well served. Relay Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Relay Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Shaw, Founder | ||
| Deborah Palestrant, Vice Strategy | ||
| MA MBA, Pres CEO | ||
| Thomas Catinazzo, Chief Officer | ||
| Andy Porter, Chief Officer | ||
| Jim Watters, Chief Research | ||
| Matthew Jacobson, Founder | ||
| Mahesh Padval, Chief Officer | ||
| Dorothee Kern, Founder | ||
| Alexis AM, CoFounder Chairman | ||
| Peter Rahmer, Chief Officer | ||
| Deborah MBA, Vice Strategy | ||
| Jeanne Gray, Chief Officer | ||
| Mark Murcko, CoFounder Director | ||
| Brian JD, Chief Secretary |
Relay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Relay Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (39.47) % | ||||
| Current Valuation | (3.09 M) | ||||
| Shares Outstanding | 167.38 M | ||||
| Shares Owned By Insiders | 1.71 % | ||||
| Shares Owned By Institutions | 98.19 % | ||||
| Number Of Shares Shorted | 11.61 M | ||||
| Price To Book | 0.94 X | ||||
| Price To Sales | 80.30 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.